Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Orphan Incentives: Voucher Price Drop Gives Some Sponsors 'Pause'

Executive Summary

Is the lower sale price making the opportunity for a priority review voucher less an incentive for orphan development?


Related Content

Rare Pediatric Disease Priority Review Voucher Not Generating New Drug Trials
A 'More Radical Idea': Set Expiration Dates For Priority Review Vouchers
Priority Review Voucher Crash: Spark's Sale To Jazz Lowest Price Since 2014
Priority Review Voucher Sales Prices Level Off In 2017
Orphan Drug Tax Credit Defense Adds To NORD's Legislative Challenges
FDA's Orphan Designation Backlog Plan Focuses On Efficiency, Not Staff
Orphan Drug Pricing Heading To Negotiating Table in US?
Priority Review Voucher Expansion Could Be Bad, Program Creator Says
Orphan Designation Requests To Get Slower Reviews
Review Voucher Program For Rare Pediatric Diseases Should Not Be Reauthorized, US FDA Says


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts